| Primary information |
|---|
| ID | antitb_1802, |
| Name | 17547385 |
| N-Terminal modification | Peptide-46 |
| C-Terminal Modification | βAla-Fpa-Tic-Oic-βAla-Dpr-Tic-Oic-βAla-Fpa-Tic-Oic-βAla-Dpr-Tic-Dpr-Dpr-Dpr-Dpr |
| Chemical Modification | Acetylation |
| Linear/Cyclic | Amidation |
| Length | βAla = beta-alanine, Fpa, 4-fluorophenylalanine, Dpr = diaminopropionic acid, Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid |
| Chirality | Linear |
| Nature | 19 |
| Source | L |
| Origin | Amphipathic, Hydrophobic |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium ranae |
| In Vitro/ In vivo | Mycobacterium ranae (ATCC 110) |
| Cell Line | MIC = 100 µM or 228 µg/mL |
| Inhibition Concentration | Both |
| Sequence | 2007 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | Not tested |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | Stimulate innate immune system |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) |
Tertiary Structure
(Technique) | Not Predicted), |